AAPL   331.50 (+2.85%)
MSFT   187.20 (+2.34%)
FB   230.77 (+1.98%)
GOOGL   1,440.02 (+1.82%)
AMZN   2,483.00 (+0.91%)
NVDA   356.80 (+1.75%)
CGC   16.51 (-0.72%)
BABA   219.55 (+0.69%)
MU   53.72 (+4.88%)
GE   7.88 (+1.81%)
TSLA   885.66 (+2.46%)
AMD   53.10 (+0.89%)
T   32.77 (+3.05%)
ACB   13.94 (-2.04%)
F   7.34 (+5.46%)
GILD   76.75 (-1.02%)
DIS   124.82 (+0.91%)
NFLX   419.60 (+1.27%)
BAC   28.11 (+4.97%)
BA   205.43 (+11.47%)
AAPL   331.50 (+2.85%)
MSFT   187.20 (+2.34%)
FB   230.77 (+1.98%)
GOOGL   1,440.02 (+1.82%)
AMZN   2,483.00 (+0.91%)
NVDA   356.80 (+1.75%)
CGC   16.51 (-0.72%)
BABA   219.55 (+0.69%)
MU   53.72 (+4.88%)
GE   7.88 (+1.81%)
TSLA   885.66 (+2.46%)
AMD   53.10 (+0.89%)
T   32.77 (+3.05%)
ACB   13.94 (-2.04%)
F   7.34 (+5.46%)
GILD   76.75 (-1.02%)
DIS   124.82 (+0.91%)
NFLX   419.60 (+1.27%)
BAC   28.11 (+4.97%)
BA   205.43 (+11.47%)
AAPL   331.50 (+2.85%)
MSFT   187.20 (+2.34%)
FB   230.77 (+1.98%)
GOOGL   1,440.02 (+1.82%)
AMZN   2,483.00 (+0.91%)
NVDA   356.80 (+1.75%)
CGC   16.51 (-0.72%)
BABA   219.55 (+0.69%)
MU   53.72 (+4.88%)
GE   7.88 (+1.81%)
TSLA   885.66 (+2.46%)
AMD   53.10 (+0.89%)
T   32.77 (+3.05%)
ACB   13.94 (-2.04%)
F   7.34 (+5.46%)
GILD   76.75 (-1.02%)
DIS   124.82 (+0.91%)
NFLX   419.60 (+1.27%)
BAC   28.11 (+4.97%)
BA   205.43 (+11.47%)
AAPL   331.50 (+2.85%)
MSFT   187.20 (+2.34%)
FB   230.77 (+1.98%)
GOOGL   1,440.02 (+1.82%)
AMZN   2,483.00 (+0.91%)
NVDA   356.80 (+1.75%)
CGC   16.51 (-0.72%)
BABA   219.55 (+0.69%)
MU   53.72 (+4.88%)
GE   7.88 (+1.81%)
TSLA   885.66 (+2.46%)
AMD   53.10 (+0.89%)
T   32.77 (+3.05%)
ACB   13.94 (-2.04%)
F   7.34 (+5.46%)
GILD   76.75 (-1.02%)
DIS   124.82 (+0.91%)
NFLX   419.60 (+1.27%)
BAC   28.11 (+4.97%)
BA   205.43 (+11.47%)
Log in

NASDAQ:KLDOKaleido Biosciences Stock Price, Forecast & News

$7.05
+0.05 (+0.71 %)
(As of 06/5/2020 04:00 PM ET)
Add
Compare
Today's Range
$6.97
Now: $7.05
$7.22
50-Day Range
$5.80
MA: $6.69
$8.01
52-Week Range
$2.82
Now: $7.05
$16.00
Volume232,576 shs
Average Volume153,336 shs
Market Capitalization$214.98 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.04
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company offers product candidates for the treatment of urea cycle disorders; hepatic encephalopathy; infections caused by multi-drug resistant bacteria; cardiometabolic and liver diseases; and immune oncology. It has a collaboration agreement with Gustave Roussy Cancer Center to develop microbiome metabolic therapies in immuno-oncology; a research collaboration with Washington University School of Medicine to explore the influence of microbiome metabolic therapies on microbial and host physiology and metabolism; and a research collaboration with Janssen to prevent childhood-onset of atopic, immune, and metabolic conditions. The company was founded in 2015 and is headquartered in Lexington, Massachusetts.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 2.3Community Rank: 2.0Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.65 out of 5 stars


Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KLDO
CUSIPN/A
CIKN/A
WebN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees91
Market Cap$214.98 million
Next Earnings Date8/6/2020 (Estimated)
OptionableNot Optionable

Receive KLDO News and Ratings via Email

Sign-up to receive the latest news and ratings for KLDO and its competitors with MarketBeat's FREE daily newsletter.

Kaleido Biosciences (NASDAQ:KLDO) Frequently Asked Questions

How has Kaleido Biosciences' stock been impacted by COVID-19 (Coronavirus)?

Kaleido Biosciences' stock was trading at $5.54 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, KLDO stock has increased by 27.3% and is now trading at $7.05. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Kaleido Biosciences?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kaleido Biosciences in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Kaleido Biosciences.

When is Kaleido Biosciences' next earnings date?

Kaleido Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Kaleido Biosciences.

How were Kaleido Biosciences' earnings last quarter?

Kaleido Biosciences Inc (NASDAQ:KLDO) announced its earnings results on Thursday, May, 14th. The company reported ($0.64) EPS for the quarter, hitting the consensus estimate of ($0.64). View Kaleido Biosciences' earnings history.

What price target have analysts set for KLDO?

2 equities research analysts have issued 1 year target prices for Kaleido Biosciences' shares. Their forecasts range from $8.00 to $8.00. On average, they anticipate Kaleido Biosciences' stock price to reach $8.00 in the next year. This suggests a possible upside of 13.5% from the stock's current price. View analysts' price targets for Kaleido Biosciences.

Has Kaleido Biosciences been receiving favorable news coverage?

Media headlines about KLDO stock have trended very negative this week, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Kaleido Biosciences earned a news impact score of -3.0 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutKaleido Biosciences.

Are investors shorting Kaleido Biosciences?

Kaleido Biosciences saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 2,380,000 shares, an increase of 7.7% from the April 30th total of 2,210,000 shares. Based on an average daily volume of 121,800 shares, the short-interest ratio is currently 19.5 days. Currently, 24.4% of the shares of the company are short sold. View Kaleido Biosciences' Current Options Chain.

Who are some of Kaleido Biosciences' key competitors?

What other stocks do shareholders of Kaleido Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kaleido Biosciences investors own include Editas Medicine (EDIT), Alector (ALEC), Gossamer Bio (GOSS), Precision BioSciences (DTIL), LogicBio Therapeutics (LOGC), NVIDIA (NVDA), Tcr2 Therapeutics (TCRR), Harpoon Therapeutics (HARP), QUALCOMM (QCOM) and Exxon Mobil (XOM).

Who are Kaleido Biosciences' key executives?

Kaleido Biosciences' management team includes the following people:
  • Mr. Michael W. Bonney, Exec. Chair (Age 62, Pay $397.5k)
  • Ms. Alison Lawton, CEO, Pres & Director (Age 59, Pay $1.04M)
  • Dr. Geoffrey von Maltzahn Ph.D., Co-Founder & Director (Age 39, Pay $35k)
  • Mr. Jerald Korn J.D., Gen. Counsel & Corp. Sec. (Age 41, Pay $464.81k)
  • Dr. Katharine Knobil M.D., Chief Medical Officer and Head of R&D (Age 55, Pay $868.03k)

When did Kaleido Biosciences IPO?

(KLDO) raised $101 million in an IPO on Thursday, February 28th 2019. The company issued 4,800,000 shares at $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan and Morgan Stanley served as the underwriters for the IPO and Canaccord Genuity was co-manager.

What is Kaleido Biosciences' stock symbol?

Kaleido Biosciences trades on the NASDAQ under the ticker symbol "KLDO."

Who are Kaleido Biosciences' major shareholders?

Kaleido Biosciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (1.84%), State Street Corp (0.48%), Geode Capital Management LLC (0.43%), Victory Capital Management Inc. (0.41%), Victory Capital Management Inc. (0.41%) and Invesco Ltd. (0.27%). Company insiders that own Kaleido Biosciences stock include Kyriazi Theo Melas, Michael W Bonney and Ventures Fund V LP Flagship. View institutional ownership trends for Kaleido Biosciences.

Which major investors are selling Kaleido Biosciences stock?

KLDO stock was sold by a variety of institutional investors in the last quarter, including Bainco International Investors, Morgan Stanley, UBS Group AG, Victory Capital Management Inc., Victory Capital Management Inc., and First Trust Advisors LP. View insider buying and selling activity for Kaleido Biosciences.

Which major investors are buying Kaleido Biosciences stock?

KLDO stock was acquired by a variety of institutional investors in the last quarter, including Invesco Ltd., BlackRock Inc., Nuveen Asset Management LLC, State Street Corp, Geode Capital Management LLC, Parametric Portfolio Associates LLC, Bank of New York Mellon Corp, and Citigroup Inc.. Company insiders that have bought Kaleido Biosciences stock in the last two years include Kyriazi Theo Melas, Michael W Bonney, and Ventures Fund V LP Flagship. View insider buying and selling activity for Kaleido Biosciences.

How do I buy shares of Kaleido Biosciences?

Shares of KLDO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Kaleido Biosciences' stock price today?

One share of KLDO stock can currently be purchased for approximately $7.05.

How big of a company is Kaleido Biosciences?

Kaleido Biosciences has a market capitalization of $214.98 million. Kaleido Biosciences employs 91 workers across the globe.

This page was last updated on 6/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.